Targets › CBS
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Metabolic and endocrine; next expected readout Jul 2027.
Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. This catabolic route allows the elimination of L-methionine and the toxic metabolite L-homocysteine. (UniProt, P35520)
Open in Phaseline: the race on CBS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Travere Therapeutics | Pegtibatinase PEG-modified cystathionine beta-synthase (CBS) enzyme replacement | CBS | Phase 3 | Homocystinuria | Jul 2027 |
Homocystinuria (2)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.